

Laura Richert

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/6071992/publications.pdf>

Version: 2024-02-01

59
papers

1,694
citations

304368

22
h-index

301761

39
g-index

60
all docs

60
docs citations

60
times ranked

3540
citing authors

#	ARTICLE	IF	CITATIONS
1	Ritonavir-boosted darunavir combined with raltegravir or tenofovir/emtricitabine in antiretroviral-naïve adults infected with HIV-1: 96 week results from the NEAT001/ANRS143 randomised non-inferiority trial. <i>Lancet, The</i> , 2014, 384, 1942-1951.	6.3	158
2	Cognitive disorders in HIV-infected patients. <i>Aids</i> , 2013, 27, 391-400.	1.0	125
3	Safety and immunogenicity of a two-dose heterologous Ad26.ZEBOV and MVA-BN-Filo Ebola vaccine regimen in adults in Europe (EBOVAC2): a randomised, observer-blind, participant-blind, placebo-controlled, phase 2 trial. <i>Lancet Infectious Diseases, The</i> , 2021, 21, 493-506.	4.6	115
4	Systems Vaccinology Identifies an Early Innate Immune Signature as a Correlate of Antibody Responses to the Ebola Vaccine rVSV-ZEBOV. <i>Cell Reports</i> , 2017, 20, 2251-2261.	2.9	107
5	Dendritic cell-based therapeutic vaccine elicits polyfunctional HIV-specific T _H cell immunity associated with control of viral load. <i>European Journal of Immunology</i> , 2014, 44, 2802-2810.	1.6	102
6	PRIMVAC vaccine adjuvanted with Alhydrogel or GLA-SE to prevent placental malaria: a first-in-human, randomised, double-blind, placebo-controlled study. <i>Lancet Infectious Diseases, The</i> , 2020, 20, 585-597.	4.6	84
7	Bone mineral density and inflammatory and bone biomarkers after darunavir/ritonavir combined with either raltegravir or tenofovir/emtricitabine in antiretroviral-naïve adults with HIV-1: a substudy of the NEAT001/ANRS143 randomised trial. <i>Lancet HIV, the</i> , 2015, 2, e464-e473.	2.1	69
8	High frequency of poor locomotor performance in HIV-infected patients. <i>Aids</i> , 2011, 25, 797-805.	1.0	65
9	A subset of HLA-DP molecules serve as ligands for the natural cytotoxicity receptor NKp44. <i>Nature Immunology</i> , 2019, 20, 1129-1137.	7.0	59
10	Tissue-resident NK cells differ in their expression profile of the nutrient transporters Glut1, CD98 and CD71. <i>PLoS ONE</i> , 2018, 13, e0201170.	1.1	46
11	Bone Mass in Prepubertal Boys Is Associated with a Gln223Arg Amino Acid Substitution in the Leptin Receptor. <i>Journal of Clinical Endocrinology and Metabolism</i> , 2007, 92, 4380-4386.	1.8	42
12	Decline in locomotor functions over time in HIV-infected patients. <i>Aids</i> , 2014, 28, 1441-1449.	1.0	42
13	Interactions Between KIR3DS1 and HLA-F Activate Natural Killer Cells to Control HCV Replication in Cell Culture. <i>Gastroenterology</i> , 2018, 155, 1366-1371.e3.	0.6	36
14	Early post-transplantation hypophosphatemia is associated with elevated FGF-23 levels. <i>European Journal of Endocrinology</i> , 2011, 164, 839-847.	1.9	35
15	Safety and immunogenicity of the live attenuated intranasal pertussis vaccine BPZE1: a phase 1b, double-blind, randomised, placebo-controlled dose-escalation study. <i>Lancet Infectious Diseases, The</i> , 2020, 20, 1290-1301.	4.6	34
16	Safety and immunogenicity of 2-dose heterologous Ad26.ZEBOV, MVA-BN-Filo Ebola vaccination in healthy and HIV-infected adults: A randomised, placebo-controlled Phase II clinical trial in Africa. <i>PLoS Medicine</i> , 2021, 18, e1003813.	3.9	34
17	Methodological issues in the use of composite endpoints in clinical trials: examples from the HIV field. <i>Clinical Trials</i> , 2010, 7, 19-35.	0.7	33
18	Biomarkers of CD4+ T-cell activation as risk factors for tuberculosis-associated immune reconstitution inflammatory syndrome. <i>Aids</i> , 2014, 28, 1593-1602.	1.0	28

#	ARTICLE	IF	CITATIONS
19	Innate immune responses to toll-like receptor stimulation are altered during the course of pregnancy. <i>Journal of Reproductive Immunology</i> , 2018, 128, 30-37.	0.8	28
20	Proliferative capacity exhibited by human liver-resident CD49a+CD25+ NK cells. <i>PLoS ONE</i> , 2017, 12, e0182532.	1.1	27
21	Safety and immunogenicity of 2-dose heterologous Ad26.ZEBOV, MVA-BN-Filo Ebola vaccination in children and adolescents in Africa: A randomised, placebo-controlled, multicentre Phase II clinical trial. <i>PLoS Medicine</i> , 2022, 19, e1003865.	3.9	27
22	The SCDâ€œWell randomized controlled trial: Effects of a mindfulnessâ€œbased intervention versus health education on mental health in patients with subjective cognitive decline (SCD). <i>Alzheimer's and Dementia: Translational Research and Clinical Interventions</i> , 2018, 4, 737-745.	1.8	26
23	Decreased HIV-Specific T-Regulatory Responses Are Associated with Effective DC-Vaccine Induced Immunity. <i>PLoS Pathogens</i> , 2015, 11, e1004752.	2.1	23
24	Diabetes and cognitive decline in a French cohort of patients infected with HIV-1. <i>Neurology</i> , 2015, 85, 1065-1073.	1.5	23
25	Ebola vaccine development: Systematic review of pre-clinical and clinical studies, and meta-analysis of determinants of antibody response variability after vaccination. <i>International Journal of Infectious Diseases</i> , 2018, 74, 83-96.	1.5	21
26	Primary HIV-1 Strains Use Nef To Downmodulate HLA-E Surface Expression. <i>Journal of Virology</i> , 2019, 93, .	1.5	21
27	Inhaled ciclesonide for outpatient treatment of COVID-19 in adults at risk of adverse outcomes: a randomised controlled trial (COVERAGE). <i>Clinical Microbiology and Infection</i> , 2022, 28, 1010-1016.	2.8	21
28	Language features in the acute phase of poststroke severe aphasia could predict the outcome. <i>European Journal of Physical and Rehabilitation Medicine</i> , 2017, 53, 249-255.	1.1	20
29	Targeting HIV-1 Env gp140 to LOX-1 Elicits Immune Responses in Rhesus Macaques. <i>PLoS ONE</i> , 2016, 11, e0153484.	1.1	20
30	Body composition and adipokines changes after initial treatment with darunavir-ritonavir plus either raltegravir or tenofovir disoproxil fumarate-emtricitabine: A substudy of the NEAT001/ANRS143 randomised trial. <i>PLoS ONE</i> , 2019, 14, e0209911.	1.1	19
31	Selective Determinants of Low Bone Mineral Mass in Adult Women with Anorexia Nervosa. <i>International Journal of Endocrinology</i> , 2013, 2013, 1-9.	0.6	16
32	Cytokine and gene transcription profiles of immune responses elicited by HIV lipopeptide vaccine in HIV-negative volunteers. <i>Aids</i> , 2013, 27, 1421-1431.	1.0	16
33	Distinct Signatures in the Receptor Repertoire Discriminate CD56bright and CD56dim Natural Killer Cells. <i>Frontiers in Immunology</i> , 2020, 11, 568927.	2.2	12
34	Engagement of TRAIL triggers degranulation and IFNÎ³ production in human natural killer cells. <i>EMBO Reports</i> , 2022, 23, .	2.0	12
35	Accelerating clinical development of HIV vaccine strategies: methodological challenges and considerations in constructing an optimised multi-arm phase I/II trial design. <i>Trials</i> , 2014, 15, 68.	0.7	11
36	HIV-1 T cell epitopes targeted to Rhesus macaque CD40 and DCIR: A comparative study of prototype dendritic cell targeting therapeutic vaccine candidates. <i>PLoS ONE</i> , 2018, 13, e0207794.	1.1	11

#	ARTICLE	IF	CITATIONS
37	Gene Expression Signatures Associated With Immune and Virological Responses to Therapeutic Vaccination With Dendritic Cells in HIV-Infected Individuals. <i>Frontiers in Immunology</i> , 2019, 10, 874.	2.2	11
38	Optimization and evaluation of Luminex performance with supernatants of antigen-stimulated peripheral blood mononuclear cells. <i>BMC Immunology</i> , 2016, 17, 44.	0.9	10
39	In-depth characterization of monocyte subsets during the course of healthy pregnancy. <i>Journal of Reproductive Immunology</i> , 2020, 141, 103151.	0.8	9
40	Changes in HIV-1 Capsid Stability Induced by Common Cytotoxic-T-Lymphocyte-Driven Viral Sequence Mutations. <i>Journal of Virology</i> , 2016, 90, 7579-7586.	1.5	8
41	No Positive Association between Vitamin D Level and Immune Responses to Hepatitis B and Streptococcus pneumoniae Vaccination in HIV-Infected Adults. <i>PLoS ONE</i> , 2016, 11, e0168640.	1.1	8
42	T Cell Immunogenicity, Gene Expression Profile, and Safety of Four Heterologous Prime-Boost Combinations of HIV Vaccine Candidates in Healthy Volunteers: Results of the Randomized Multi-Arm Phase I/II ANRS VRI01 Trial. <i>Journal of Immunology</i> , 2022, 208, 2663-2674.	0.4	8
43	Recent developments in clinical trial designs for HIV vaccine research. <i>Human Vaccines and Immunotherapeutics</i> , 2015, 11, 1022-1029.	1.4	7
44	Host and disease factors are associated with cognitive function in European HIV-infected adults prior to initiation of antiretroviral therapy. <i>HIV Medicine</i> , 2016, 17, 471-478.	1.0	7
45	Changes in Cognitive Function Over 96 Weeks in Naive Patients Randomized to Darunavir/Ritonavir Plus Either Raltegravir or Tenofovir/Emtricitabine. <i>Journal of Acquired Immune Deficiency Syndromes (1999)</i> , 2017, 74, 185-192.	0.9	7
46	Evaluation of the template letter regarding the disclosure of genetic information within the family in France. <i>Journal of Community Genetics</i> , 2019, 10, 489-499.	0.5	7
47	Population pharmacokinetics and pharmacogenetics of ritonavir-boosted darunavir in the presence of raltegravir or tenofovir disoproxil fumarate/emtricitabine in HIV-infected adults and the relationship with virological response: a sub-study of the NEAT001/ANRS143 randomized trial. <i>Journal of Antimicrobial Chemotherapy</i> , 2020, 75, 628-639.	1.3	7
48	The Transcription Factor Promyelocytic Leukemia Zinc Finger Protein Is Associated With Expression of Liver-Homing Receptors on Human Blood CD56bright Natural Killer Cells. <i>Hepatology Communications</i> , 2020, 4, 409-424.	2.0	7
49	Patient-Reported Outcomes in First-Line Antiretroviral Therapy: Results From NEAT001/ANRS143 Trial Comparing Darunavir/Ritonavir in Combination With Tenofovir/Emtricitabine or Raltegravir. <i>Journal of Acquired Immune Deficiency Syndromes (1999)</i> , 2018, 79, 519-526.	0.9	5
50	Multi-arm, multi-stage randomised controlled trials for evaluating therapeutic HIV cure interventions. <i>Lancet HIV</i> , 2019, 6, e334-e340.	2.1	5
51	Early CD4+ T Cell Responses Are Associated with Subsequent CD8+ T Cell Responses to an rAd5-Based Prophylactic Prime-Boost HIV Vaccine Strategy. <i>PLoS ONE</i> , 2016, 11, e0152952.	1.1	4
52	A randomized double-blind placebo-controlled trial to investigate the effects of nasal calcitonin on bone microarchitecture measured by high-resolution peripheral quantitative computerized tomography in postmenopausal women – Study protocol. <i>Trials</i> , 2008, 9, 19.	0.7	3
53	Handgrip Strength Is Only Weakly Correlated With Physical Function in Well-Controlled HIV Infection. <i>Journal of Acquired Immune Deficiency Syndromes (1999)</i> , 2014, 65, e25-e27.	0.9	3
54	Methodological issues of non-inferiority trials in HIV-infected patients: a need for consensus?. <i>Aids</i> , 2008, 22, 996-997.	1.0	2

#	ARTICLE	IF	CITATIONS
55	Is the current use of "positivity"™ thresholds meaningful for evaluating HIV-vaccine immunogenicity endpoints?. <i>Aids</i> , 2013, 27, 1362-1365.	1.0	2
56	Analyzing cellular immunogenicity in vaccine clinical trials: a new statistical method including non-specific responses for accurate estimation of vaccine effect. <i>Journal of Immunological Methods</i> , 2020, 477, 112711.	0.6	2
57	Patient Self-Reported Adherence to Ritonavir-Boosted Darunavir Combined With Either Raltegravir or Tenofovir Disoproxil Fumarate/Emtricitabine in the NEAT001/ANRS143 Trial. <i>Journal of Acquired Immune Deficiency Syndromes (1999)</i> , 2018, 79, 481-490.	0.9	1
58	NK Cell Subset Redistribution and Antibody Dependent Activation after Ebola Vaccination in Africans. <i>Vaccines</i> , 2022, 10, 884.	2.1	1
59	Influence of the Antiretroviral Regimen on the Early Changes in Plasma HIV RNA and Immune Activation at Initiation of Antiretroviral Therapy in Naïve HIV-1™ Infected Patients. <i>Journal of Acquired Immune Deficiency Syndromes (1999)</i> , 2021, 86, e146-e149.	0.9	0